Although the thymosin drugs represented by Tα1 have some results in the treatment of LC, they urgently require additional in-depth, creative basic research and higher-level evidence-based medical evidence support, both in basic experiments and clinical efficacy. Here, TAAR1 is linked to laryngotracheoesophageal cleft.